Each circle represents an individual sample
of human breast carcinoma (n = 392 for TCGA dataset; n = 261 for Bittner dataset).
Fulvestrant treatment alters MDM2 protein turnover and sensitivity
of human breast carcinoma cells to chemotherapeutic drugs.
Trastuzumab is a humanized monoclonal antibody that targets the HER2 receptor, which is overexpressed in approximately 20 — 30 %
of human breast carcinomas [11].
Not exact matches
Dr. Jos Jonkers» research group studies the genetic basis
of human breast cancer, using advanced mouse models for p53 - induced
breast cancer, BRCA1 - and BRCA2 - associated hereditary
breast cancer, and E-cadherin mutated invasive lobular
carcinoma.
Research Paper Immunohistochemical Expression
of Cyclin D1 in Invasive Ductal
Carcinoma of Human Breast Mahmoud Assem, Eman Ahmed Youssef, Radwa Mohammed Rashad, Mona Abdel - Hamed Yahia Oncomedicine 2017; 2: 80 - 87.
Tags: aspirin, Bezos, bioengineering,
Breast Cancer, Cameron Turtle, Cancer etiology - prevention - outcomes, CAR t - cell, Clinical Research, Colorectal Cancer, genome, hiv, hiv vaccine, hiv vaccine trials network,
Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell
carcinoma, metastasis, Molecular basis
of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral cancers
Here we report that HB1.F3 NSCs can be engineered to express and secrete functional full - length HER2 - specific
human immunoglobulin molecules that can selectively bind to and inhibit the proliferation
of HER2 - positive
breast carcinoma cells.
Studies
of Gluts in
human tumors have shown a significant increase in the abundance
of Glut1 and Glut3 mRNA in cancers
of the esophagus, colon, and pancreas, overexpression
of Glut1 and Glut3 mRNA and Glut1 protein expression in head and neck tumors and Glut1 protein overexpression in
breast and renal cell
carcinomas
The curcumin metabolite tetrahydrocurcumin decreases the activity
of the phase III transporters in
human cervical
carcinoma and
breast cancer cell lines.